Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
New York Medical College, Valhalla, NY, USA.
Expert Rev Neurother. 2024 Aug;24(8):761-771. doi: 10.1080/14737175.2024.2370349. Epub 2024 Jul 23.
Long-acting injectable (LAI) antipsychotic medications can help improve treatment adherence in patients with schizophrenia and bipolar disorder. Despite this, they are underutilized. In 2003, intramuscular risperidone became the first available LAI atypical antipsychotic medication, and since then, a number of competing long-acting risperidone formulations have been brought to market, with additional options under active development. These include intramuscular, subcutaneous, long-acting oral, and implantable formulations.
This review summarizes currently available and emerging long-acting risperidone formulations, including efficacy and safety data, and practical considerations aimed to help prescribers distinguish one formulation from another.
There is an expanding number of currently available LAI antipsychotic medications giving patients and providers an opportunity to personalize and individualize care. Rates of adherence to treatment in patients with schizophrenia and bipolar disorder are low, and individualizing care can help improve this. The risperidone LAI treatment landscape includes five options approved by the U.S. Food and Drug Administration, with others under clinical development. These options differ in regard to mode of administration, approved indications, available dose strengths, injection intervals, needle size, injection volume, storage, and other variables. Prescribers should be familiar with these differing options to help patients find the best fit for their individual needs.
长效注射（LAI）抗精神病药物有助于提高精神分裂症和双相情感障碍患者的治疗依从性。尽管如此，它们的使用仍不充分。2003 年，肌肉注射利培酮成为第一种可用的 LAI 非典型抗精神病药物，此后，许多具有竞争的长效利培酮制剂已投放市场，还有更多的选择正在积极开发中。这些制剂包括肌肉内、皮下、长效口服和可植入制剂。
本文综述了目前可用和新兴的长效利培酮制剂，包括疗效和安全性数据，并考虑了一些实际问题，旨在帮助处方者区分不同的制剂。
目前有越来越多的 LAI 抗精神病药物可供选择，这为患者和提供者提供了个性化和个体化治疗的机会。精神分裂症和双相情感障碍患者的治疗依从率较低，而个体化治疗有助于改善这一情况。利培酮 LAI 治疗方案包括美国食品和药物管理局批准的五种选择，还有其他选择正在临床开发中。这些选择在给药方式、批准的适应证、可用的剂量强度、注射间隔、针头大小、注射体积、储存和其他变量方面存在差异。处方者应熟悉这些不同的选择，以帮助患者找到最适合其个人需求的方案。
